Brian Park, PharmD

Drug Information Specialist https://www.oncologynurseadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer

Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Brian Park, PharmD

October 25, 2019

FDA Warns of Possible Interstitial Lung Disease, Pneumonitis With Certain Breast Cancer Drugs

Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams.

Brian Park, PharmD

September 18, 2019

Cancer Risk From Recalled ARBs “Likely Much Lower” Than Initially Estimated, Says FDA

The FDA is working in close collaboration with global regulatory partners to evaluate the controls in place and publish guidance on preventing unacceptable levels of nitrosamine in drugs.

Brian Park, PharmD

September 10, 2019

Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval

The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)

Brian Park, PharmD

August 16, 2019